In this Review, Gilgunn and colleagues consider how the specificity and sensitivity of the PSA assay has changed over the past 20 years and explain how the analysis of aberrant PSA glycosylation patterns could be used to investigate prostate cancer.
- Sarah Gilgunn
- Paul J. Conroy
- Richard J. O'Kennedy